Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15145214rdf:typepubmed:Citationlld:pubmed
pubmed-article:15145214lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C0002895lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C0014762lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C2323499lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C0205307lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C0005221lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C1441547lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:15145214lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:15145214pubmed:issue5lld:pubmed
pubmed-article:15145214pubmed:dateCreated2004-5-17lld:pubmed
pubmed-article:15145214pubmed:abstractTextRecent improvements in human beta-globin vector design have fueled interest in gene therapy approaches to the treatment of human thalassemia and sickle cell disease (SCD). The present study was undertaken to determine whether human beta-globin mRNA and protein could be obtained in the erythroid progeny of more primitive human target cells transduced with a retrovirus containing murine stem cell virus long terminal repeats, a phosphoglycerate kinase promoter driving the expression of a green fluorescence protein (GFP) cDNA, and an anti-sickling beta-globin (beta87(+)) gene under the control of an HS2, HS3, HS4 enhancer cassette.lld:pubmed
pubmed-article:15145214pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15145214pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15145214pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15145214pubmed:languageenglld:pubmed
pubmed-article:15145214pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15145214pubmed:citationSubsetIMlld:pubmed
pubmed-article:15145214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15145214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15145214pubmed:statusMEDLINElld:pubmed
pubmed-article:15145214pubmed:monthMaylld:pubmed
pubmed-article:15145214pubmed:issn0301-472Xlld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:EavesConnieClld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:LeboulchPhili...lld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:HoffmanRonald...lld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:HumphriesR...lld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:NagelRonald...lld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:FabryMary EMElld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:PawliukRobert...lld:pubmed
pubmed-article:15145214pubmed:authorpubmed-author:OhIl-HoanIHlld:pubmed
pubmed-article:15145214pubmed:issnTypePrintlld:pubmed
pubmed-article:15145214pubmed:volume32lld:pubmed
pubmed-article:15145214pubmed:ownerNLMlld:pubmed
pubmed-article:15145214pubmed:authorsCompleteYlld:pubmed
pubmed-article:15145214pubmed:pagination461-9lld:pubmed
pubmed-article:15145214pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:meshHeadingpubmed-meshheading:15145214...lld:pubmed
pubmed-article:15145214pubmed:year2004lld:pubmed
pubmed-article:15145214pubmed:articleTitleExpression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.lld:pubmed
pubmed-article:15145214pubmed:affiliationTerry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada.lld:pubmed
pubmed-article:15145214pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15145214pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15145214pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15145214lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15145214lld:pubmed